Weight loss drug popularity
In 2017, Nova Nordisk introduced Ozempic to the market as a drug that can be used to treat type 2 diabetes. However, healthcare professionals soon observed that some individuals who use this drug experience side effects of appetite suppression and subsequent weight loss. The weight loss popularity of this drug resulted in the development of Wegovy, a higher-dose version of Ozempic.
Nova Nordisk produces Ozempic, Wegovy and Rybelsus, each containing the active ingredient semaglutide.
What is semaglutide?
Semaglutide is a medication that aids in reducing blood sugar levels. It achieves this by mimicking a hormone named GLP-1, produced by the body to aid in digestion after a meal. GLP-1 is also responsible for reducing hunger and creating a sensation of fullness.
What is tirzepatide?
Along with Ozempic and Wegovy, Mounjaro has gained popularity for its weight loss effects. Mounjaro’s active ingredient is Tirzepatide, which is like semaglutide.
Tirzepatide acts as both a dual GLP-1 agonist and GIP agonist, providing similar benefits to GLP-1 medications like semaglutide. It is currently used as a second-line diabetes medication, just like GLP-1 medications, and administered as a once-weekly subcutaneous injection.
Eli Lilly is the manufacturer of two medications that contain tirzepatide:
- Mounjaro
- Zepbound
-
Ryan J. Duplechin Principal Montgomery, AL -
Mary Cam Raybon Associate Montgomery, AL
Alabama Opioid Settlements: $728 Million & ClimbingApril 25, 2024
New Lawsuits Filed Over Ozempic Side EffectsJanuary 24, 2024
Potential Health Problems
In 2023, the Food and Drug Administration (FDA) reported receiving complaints indicating safety concerns for these drugs, including the risk of serious and life-threatening intestinal blockage. It is now being evaluated whether additional warnings are necessary due to reports of intestinal obstruction.
Recent studies show drugs such as Wegovy, Ozempic and Mounjaro may increase the risk of potentially fatal intestinal blockages or obstructions, which often require major surgery. Intestinal blockage signs and symptoms may include:
- Abdominal cramps
- Bloating
- Constipation
- Vomiting
- Difficulty passing gas
Along with intestinal blockage, the FDA has also received reports of stomach paralysis. Stomach paralysis, also known as gastropareses, prevents the stomach’s nerves and muscles from working properly, leaving food sitting too long. Symptoms of gastroparesis may include:
- Indigestion
- Nausea
- Vomiting
- Malnutrition
- Bloating
- Feeling full quickly
- Upper abdominal pain
- Loss of appetite
- Constipation
Do you have a case?
You may have a case if:
- You started the medication at age 75 or younger.
- Took one of the name-brand drugs: Ozempic, Wegovy and Mounjaro
- Required emergency room visit or hospital admission for vomiting.
- Had a diagnosis of gastroparesis, gastric stasis, stomach paralysis or gastric obstruction while taking the drug or within 30 days of stopping.
Why choose Beasley Allen?
For more than four decades, Beasley Allen has fought against pharmaceutical and drug companies, recovering billions for our clients nationwide.
Filing a case with Beasley Allen can help you seek compensation for any damages or injuries you may have suffered because of using a medication containing semaglutide, such as Ozempic, Wegovy or Mounjaro.
If you became ill after using one of these medications, do not face additional health complications alone. We offer a free case evaluation to determine if you may be eligible for compensation and can guide you through the legal process every step of the way.
Related News
Alabama Opioid Settlements: $728 Million & Climbing
The opioid epidemic swept across the United States, leaving a trail of addiction, overdose, and…
Alabama Reaches $220 Million Settlement with Opioid Distributors
The State of Alabama has settled with two opioid distributors, resolving litigation for their roles…
New Lawsuits Filed Over Ozempic Side Effects
Many of us have come across advertisements for Ozempic, an FDA-approved injection used to treat…
